Journal Articles ESMO Open Year : 2022

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

Abstract

Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) agents have only moderate antitumor activity in some advanced solid tumors (AST), including breast cancer (BC), prostate cancer (PC), cervical cancer (CC), and head and neck cancer (HNC). Combining anti-PD-L1 with anti-cytotoxic T-lymphocyte-associated protein (CTLA) and chemotherapy may significantly improve efficacy.

Dates and versions

hal-03923625 , version 1 (04-01-2023)

Identifiers

Cite

C. Vicier, N. Isambert, C. Cropet, M. Hamimed, L. Osanno, et al.. MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. ESMO Open, 2022, 7 (6), pp.100646. ⟨10.1016/j.esmoop.2022.100646⟩. ⟨hal-03923625⟩
26 View
0 Download

Altmetric

Share

More